Calando is a clinical stage nanobiotechnology company at the forefront of RNAi therapeutics. We develop nanoparticle therapeutics that use our patented sugar (cyclodextrin)-based polymer technologies as a drug delivery system for siRNA. Our products are based on pioneering technology invented in the Chemical Engineering Department of the California Institute of Technology. Engineered to reduce the debilitating effects of cancer treatment, our proprietary molecules are designed to improve the safety and efficacy of cancer therapeutics using siRNA as the active ingredient. The target-agnostic platform technology has the potential to be applied to a wide range of diseases beyond cancer as well as to therapeutic classes beyond siRNA therapeutics. In 2009, we successfully completed a Phase 1 clinical study with our first anti-cancer drug and therapeutic candidate, IT-101. IT-101, along with Calando's drug delivery platform, Cyclosert™, now is partnered for further development to Cerulean Pharma Inc.
View Top Employees from Calando Pharmaceuticals , Inc.| Website | http://www.calandopharma.com |
| Revenue | $11 million |
| Employees | View employees |
| Address | 225 South Lake Ave., 3rd Fl, Pasadena, California 91101, US |
| Phone | (626) 304-3400 |
| Fax | (626) 304-3401 |
| Industry | Biotechnology, Pharmaceuticals, Healthcare |
| Competitors | Biokine Therapeutics Ltd., Nucleonics , Inc., Quark Pharmaceuticals Inc, Silence Therapeutics plc, Sirnaomics |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies |
Looking for a particular Calando Pharmaceuticals , Inc. employee's phone or email?
Calando Pharmaceuticals , Inc. Questions
The Calando Pharmaceuticals , Inc. annual revenue was $11 million in 2023.
Calando Pharmaceuticals , Inc. is based in Pasadena, California.
The NAICS codes for Calando Pharmaceuticals , Inc. are [54, 5417, 541].
The SIC codes for Calando Pharmaceuticals , Inc. are [283, 28].
